Mark Elliott Boulding, Executive VP and CLO of PTC Therapeutics ($PTCT), sold about $7.0 million in company shares through 51 open market transactions over the past year. His most recent sale occurred on February 19, 2026. These sales rank 1,494th among 11,678 insiders in our database, where the average is $8.6 million across roughly six trades. Boulding made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 19, 2026 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 212 | $68.54 | 105,802.0000 | 88,311,494 | 0.20% | 0.00% |
| Feb. 19, 2026 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 590 | $69.82 | 105,212.0000 | 88,311,494 | 0.56% | 0.00% |
| Feb. 19, 2026 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 1629 | $69.82 | 106,014.0000 | 88,311,494 | 1.51% | 0.00% |
| Feb. 19, 2026 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 588 | $68.54 | 107,643.0000 | 88,311,494 | 0.54% | 0.00% |
| Feb. 17, 2026 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 2 | $70.13 | 111,312.0000 | 88,311,494 | 0.00% | 0.00% |
| Feb. 17, 2026 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 2811 | $69.29 | 111,314.0000 | 88,311,494 | 2.46% | 0.00% |
| Feb. 17, 2026 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Common Stock | 2813 | $25.69 | 114,125.0000 | 88,311,494 | 2.53% | 0.00% |
| Feb. 17, 2026 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Stock Option (Right to Buy) | 2813 | $0.00 | 22,501.0000 | 88,311,494 | 11.11% | 0.00% |
| Feb. 18, 2026 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 3081 | $69.36 | 108,231.0000 | 88,311,494 | 2.77% | 0.00% |
| Jan. 8, 2026 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 1286 | $76.45 | 113,626.0000 | 88,311,494 | 1.12% | 0.00% |
| Jan. 8, 2026 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 265 | $77.07 | 114,912.0000 | 88,311,494 | 0.23% | 0.00% |
| Jan. 8, 2026 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 2482 | $76.56 | 115,177.0000 | 88,311,494 | 2.11% | 0.00% |
| Jan. 9, 2026 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 107 | $79.52 | 111,312.0000 | 88,311,494 | 0.10% | 0.00% |
| Jan. 9, 2026 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 686 | $78.71 | 111,419.0000 | 88,311,494 | 0.61% | 0.00% |
| Jan. 9, 2026 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 1521 | $77.46 | 112,105.0000 | 88,311,494 | 1.34% | 0.00% |
| Jan. 7, 2026 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 1503 | $77.48 | 117,659.0000 | 88,311,494 | 1.26% | 0.00% |
| Jan. 7, 2026 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Stock Option (Right to Buy) | 751 | $0.00 | 0.0000 | 88,311,494 | 100.00% | 0.00% |
| Jan. 7, 2026 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Stock Option (Right to Buy) | 2625 | $0.00 | 751.0000 | 88,311,494 | 77.75% | 0.00% |
| Jan. 7, 2026 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 11 | $78.98 | 117,659.0000 | 88,311,494 | 0.01% | 0.00% |
| Jan. 7, 2026 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 269 | $77.92 | 117,670.0000 | 88,311,494 | 0.23% | 0.00% |
| Jan. 7, 2026 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 471 | $77.10 | 117,939.0000 | 88,311,494 | 0.40% | 0.00% |
| Jan. 7, 2026 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Common Stock | 751 | $38.10 | 118,410.0000 | 88,311,494 | 0.64% | 0.00% |
| Jan. 7, 2026 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 38 | $78.60 | 117,659.0000 | 88,311,494 | 0.03% | 0.00% |
| Jan. 7, 2026 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 949 | $77.91 | 117,697.0000 | 88,311,494 | 0.80% | 0.00% |
| Jan. 7, 2026 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 1638 | $77.11 | 118,646.0000 | 88,311,494 | 1.36% | 0.00% |
| Jan. 7, 2026 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Common Stock | 2625 | $38.10 | 120,284.0000 | 88,311,494 | 2.23% | 0.00% |
| Jan. 6, 2026 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 1739 | $76.95 | 119,162.0000 | 88,311,494 | 1.44% | 0.00% |
| Jan. 5, 2026 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 1035 | $76.10 | 121,009.0000 | 88,311,494 | 0.85% | 0.00% |
| Jan. 5, 2026 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Stock Option (Right to Buy) | 2266 | $0.00 | 9,063.0000 | 88,311,494 | 20.00% | 0.00% |
| Jan. 2, 2026 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | A | Stock Option (Right to Buy) | 42500 | $0.00 | 42,500.0000 | 88,311,494 | 9999.99% | 0.05% |
| Jan. 5, 2026 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 108 | $76.79 | 120,901.0000 | 88,311,494 | 0.09% | 0.00% |
| Jan. 5, 2026 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 1123 | $74.92 | 122,044.0000 | 88,311,494 | 0.91% | 0.00% |
| Jan. 5, 2026 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Common Stock | 2266 | $39.42 | 123,167.0000 | 88,311,494 | 1.87% | 0.00% |
| Jan. 2, 2026 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | A | Common Stock | 17000 | $0.00 | 120,901.0000 | 88,311,494 | 16.36% | 0.02% |
| Nov. 17, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 1843 | $75.64 | 104,870.0000 | 87,115,369 | 1.73% | 0.00% |
| Nov. 17, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Common Stock | 2812 | $25.69 | 106,713.0000 | 87,115,369 | 2.71% | 0.00% |
| Nov. 17, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Stock Option (Right to Buy) | 2812 | $0.00 | 25,314.0000 | 87,115,369 | 10.00% | 0.00% |
| Nov. 17, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 192 | $77.18 | 103,901.0000 | 87,115,369 | 0.18% | 0.00% |
| Nov. 17, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 777 | $76.53 | 104,093.0000 | 87,115,369 | 0.74% | 0.00% |
| Oct. 7, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 1306 | $63.80 | 104,213.0000 | 87,115,369 | 1.24% | 0.00% |
| Oct. 7, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Common Stock | 3375 | $38.10 | 107,276.0000 | 87,115,369 | 3.25% | 0.00% |
| Oct. 7, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Stock Option (Right to Buy) | 3375 | $0.00 | 3,376.0000 | 87,115,369 | 49.99% | 0.00% |
| Oct. 7, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 312 | $64.97 | 103,901.0000 | 87,115,369 | 0.30% | 0.00% |
| Oct. 7, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 1757 | $62.89 | 105,519.0000 | 87,115,369 | 1.64% | 0.00% |
| Oct. 3, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Common Stock | 2265 | $39.42 | 106,166.0000 | 87,115,369 | 2.18% | 0.00% |
| Oct. 3, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 906 | $66.63 | 103,901.0000 | 87,115,369 | 0.86% | 0.00% |
| Oct. 3, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 824 | $65.73 | 104,807.0000 | 87,115,369 | 0.78% | 0.00% |
| Oct. 3, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 536 | $64.43 | 105,631.0000 | 87,115,369 | 0.50% | 0.00% |
| Oct. 3, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Common Stock | 2266 | $39.42 | 106,167.0000 | 87,115,369 | 2.18% | 0.00% |
| Oct. 3, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 1500 | $67.15 | 103,901.0000 | 87,115,369 | 1.42% | 0.00% |
| Oct. 3, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 6124 | $65.47 | 112,801.0000 | 87,115,369 | 5.15% | 0.01% |
| Oct. 3, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 3100 | $64.43 | 118,925.0000 | 87,115,369 | 2.54% | 0.00% |
| Oct. 3, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 7400 | $66.44 | 105,401.0000 | 87,115,369 | 6.56% | 0.01% |
| Oct. 3, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Common Stock | 18124 | $39.42 | 122,025.0000 | 87,115,369 | 17.44% | 0.02% |
| Oct. 6, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Stock Option (Right to Buy) | 2266 | $0.00 | 11,329.0000 | 87,115,369 | 16.67% | 0.00% |
| Oct. 3, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Stock Option (Right to Buy) | 2265 | $0.00 | 13,595.0000 | 87,115,369 | 14.28% | 0.00% |
| Oct. 3, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Stock Option (Right to Buy) | 2266 | $0.00 | 15,860.0000 | 87,115,369 | 12.50% | 0.00% |
| Oct. 3, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Stock Option (Right to Buy) | 18124 | $0.00 | 18,126.0000 | 87,115,369 | 50.00% | 0.02% |
| Oct. 6, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 2266 | $65.07 | 103,901.0000 | 87,115,369 | 2.13% | 0.00% |
| Oct. 6, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Common Stock | 2266 | $39.42 | 106,167.0000 | 87,115,369 | 2.18% | 0.00% |
| Oct. 3, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 877 | $66.67 | 103,901.0000 | 87,115,369 | 0.84% | 0.00% |
| Oct. 3, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 838 | $65.72 | 104,778.0000 | 87,115,369 | 0.79% | 0.00% |
| Oct. 3, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 550 | $64.44 | 105,616.0000 | 87,115,369 | 0.52% | 0.00% |
| Sept. 12, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Stock Option (Right to Buy) | 1019 | $0.00 | 7,656.0000 | 78,151,240 | 11.75% | 0.00% |
| Sept. 11, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Common Stock | 17838 | $38.10 | 121,739.0000 | 78,151,240 | 17.17% | 0.02% |
| Sept. 11, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 17838 | $61.00 | 103,901.0000 | 78,151,240 | 14.65% | 0.02% |
| Sept. 11, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Common Stock | 2356 | $38.10 | 106,257.0000 | 78,151,240 | 2.27% | 0.00% |
| Sept. 11, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 2356 | $61.00 | 103,901.0000 | 78,151,240 | 2.22% | 0.00% |
| Sept. 11, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Common Stock | 2470 | $38.10 | 106,371.0000 | 78,151,240 | 2.38% | 0.00% |
| Sept. 11, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 2470 | $61.00 | 103,901.0000 | 78,151,240 | 2.32% | 0.00% |
| Sept. 12, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Common Stock | 22661 | $38.10 | 126,562.0000 | 78,151,240 | 21.81% | 0.03% |
| Sept. 12, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 22117 | $61.33 | 104,445.0000 | 78,151,240 | 17.48% | 0.03% |
| Sept. 12, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 544 | $62.09 | 103,901.0000 | 78,151,240 | 0.52% | 0.00% |
| Sept. 12, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Common Stock | 1019 | $38.10 | 104,920.0000 | 78,151,240 | 0.98% | 0.00% |
| Sept. 12, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 1019 | $61.31 | 103,901.0000 | 78,151,240 | 0.97% | 0.00% |
| Sept. 12, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Common Stock | 905 | $38.10 | 104,806.0000 | 78,151,240 | 0.87% | 0.00% |
| Sept. 12, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 905 | $61.21 | 103,901.0000 | 78,151,240 | 0.86% | 0.00% |
| Sept. 11, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Stock Option (Right to Buy) | 17838 | $0.00 | 36,162.0000 | 78,151,240 | 33.03% | 0.02% |
| Sept. 11, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Stock Option (Right to Buy) | 2356 | $0.00 | 33,806.0000 | 78,151,240 | 6.52% | 0.00% |
| Sept. 11, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Stock Option (Right to Buy) | 2470 | $0.00 | 31,336.0000 | 78,151,240 | 7.31% | 0.00% |
| Sept. 12, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Stock Option (Right to Buy) | 22661 | $0.00 | 8,675.0000 | 78,151,240 | 72.32% | 0.03% |
| Sept. 12, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Stock Option (Right to Buy) | 905 | $0.00 | 6,751.0000 | 78,151,240 | 11.82% | 0.00% |
| Aug. 15, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Stock Option (Right to Buy) | 2813 | $0.00 | 24,899.0000 | 78,151,240 | 10.15% | 0.00% |
| Aug. 15, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Common Stock | 2813 | $25.69 | 106,714.0000 | 78,151,240 | 2.71% | 0.00% |
| Aug. 15, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 2813 | $48.58 | 103,901.0000 | 78,151,240 | 2.64% | 0.00% |
| May 16, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 883 | $46.02 | 103,901.0000 | 86,385,922 | 0.84% | 0.00% |
| May 15, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Common Stock | 1929 | $25.69 | 105,830.0000 | 86,385,922 | 1.86% | 0.00% |
| May 16, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Common Stock | 883 | $25.69 | 104,784.0000 | 86,385,922 | 0.85% | 0.00% |
| May 15, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 1929 | $46.18 | 103,901.0000 | 86,385,922 | 1.82% | 0.00% |
| May 15, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Stock Option (Right to Buy) | 1929 | $0.00 | 28,595.0000 | 86,385,922 | 6.32% | 0.00% |
| May 16, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Stock Option (Right to Buy) | 883 | $0.00 | 27,712.0000 | 86,385,922 | 3.09% | 0.00% |
| March 12, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Stock Option (Right to Buy) | 13126 | $0.00 | 0.0000 | 76,845,055 | 100.00% | 0.02% |
| March 12, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Common Stock | 2395 | $33.02 | 106,296.0000 | 76,845,055 | 2.31% | 0.00% |
| March 12, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 13126 | $53.31 | 103,901.0000 | 76,845,055 | 11.22% | 0.02% |
| March 12, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Common Stock | 13126 | $33.02 | 117,027.0000 | 76,845,055 | 12.63% | 0.02% |
| March 12, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Stock Option (Right to Buy) | 2395 | $0.00 | 0.0000 | 76,845,055 | 100.00% | 0.00% |
| March 12, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 2395 | $53.23 | 103,901.0000 | 76,845,055 | 2.25% | 0.00% |
| March 10, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Common Stock | 11398 | $33.02 | 115,299.0000 | 76,845,055 | 10.97% | 0.01% |
| March 11, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Stock Option (Right to Buy) | 1719 | $0.00 | 2,395.0000 | 76,845,055 | 41.78% | 0.00% |
| March 11, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Stock Option (Right to Buy) | 5662 | $0.00 | 13,126.0000 | 76,845,055 | 30.14% | 0.01% |
| March 10, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Stock Option (Right to Buy) | 11249 | $0.00 | 33,751.0000 | 76,845,055 | 25.00% | 0.01% |
| March 10, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Stock Option (Right to Buy) | 11398 | $0.00 | 4,114.0000 | 76,845,055 | 73.48% | 0.01% |
| March 10, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Stock Option (Right to Buy) | 45392 | $0.00 | 18,788.0000 | 76,845,055 | 70.73% | 0.06% |
| March 11, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 1719 | $53.01 | 103,901.0000 | 76,845,055 | 1.63% | 0.00% |
| March 11, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Common Stock | 1719 | $33.02 | 105,620.0000 | 76,845,055 | 1.65% | 0.00% |
| March 11, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 5662 | $53.02 | 103,901.0000 | 76,845,055 | 5.17% | 0.01% |
| March 11, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Common Stock | 5662 | $33.02 | 109,563.0000 | 76,845,055 | 5.45% | 0.01% |
| March 10, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 7762 | $53.05 | 103,901.0000 | 76,845,055 | 6.95% | 0.01% |
| March 10, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 3487 | $52.24 | 111,663.0000 | 76,845,055 | 3.03% | 0.00% |
| March 10, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Common Stock | 11249 | $25.69 | 115,150.0000 | 76,845,055 | 10.83% | 0.01% |
| March 10, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Common Stock | 45392 | $33.02 | 149,293.0000 | 76,845,055 | 43.69% | 0.06% |
| March 10, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 45392 | $53.15 | 103,901.0000 | 76,845,055 | 30.40% | 0.06% |
| March 10, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 11398 | $53.12 | 103,901.0000 | 76,845,055 | 9.89% | 0.01% |
| Feb. 20, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 1614 | $50.12 | 103,901.0000 | 76,845,055 | 1.53% | 0.00% |
| Feb. 19, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 1333 | $50.10 | 105,515.0000 | 76,845,055 | 1.25% | 0.00% |
| Jan. 7, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 1543 | $45.34 | 108,846.0000 | 76,845,055 | 1.40% | 0.00% |
| Jan. 8, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 1998 | $44.50 | 106,848.0000 | 76,845,055 | 1.84% | 0.00% |
| Jan. 3, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | A | Common Stock | 18000 | $0.00 | 110,389.0000 | 76,845,055 | 19.48% | 0.02% |
| Jan. 3, 2025 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | A | Stock Option (Right to Buy) | 45000 | $0.00 | 45,000.0000 | 76,845,055 | 9999.99% | 0.06% |
| Dec. 3, 2024 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 600 | $53.04 | 92,389.0000 | 76,925,523 | 0.65% | 0.00% |
| Dec. 3, 2024 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Stock Option (Right to Buy) | 1988 | $0.00 | 15,512.0000 | 76,925,523 | 11.36% | 0.00% |
| Dec. 3, 2024 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Stock Option (Right to Buy) | 7720 | $0.00 | 61,110.0000 | 76,925,523 | 11.22% | 0.01% |
| Dec. 3, 2024 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Stock Option (Right to Buy) | 600 | $0.00 | 3,070.0000 | 76,925,523 | 16.35% | 0.00% |
| Dec. 2, 2024 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Stock Option (Right to Buy) | 83640 | $0.00 | 0.0000 | 76,925,523 | 100.00% | 0.11% |
| Dec. 2, 2024 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Stock Option (Right to Buy) | 1960 | $0.00 | 83,640.0000 | 76,925,523 | 2.29% | 0.00% |
| Dec. 3, 2024 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 88 | $54.14 | 92,389.0000 | 76,925,523 | 0.10% | 0.00% |
| Dec. 3, 2024 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 1900 | $53.13 | 92,477.0000 | 76,925,523 | 2.01% | 0.00% |
| Dec. 3, 2024 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Common Stock | 1988 | $33.02 | 94,377.0000 | 76,925,523 | 2.15% | 0.00% |
| Dec. 3, 2024 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 1405 | $54.05 | 92,389.0000 | 76,925,523 | 1.50% | 0.00% |
| Dec. 3, 2024 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 6315 | $53.14 | 93,794.0000 | 76,925,523 | 6.31% | 0.01% |
| Dec. 3, 2024 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Common Stock | 7720 | $33.02 | 100,109.0000 | 76,925,523 | 8.36% | 0.01% |
| Dec. 3, 2024 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Common Stock | 600 | $33.02 | 92,989.0000 | 76,925,523 | 0.65% | 0.00% |
| Dec. 2, 2024 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 83640 | $52.26 | 92,389.0000 | 76,925,523 | 47.51% | 0.11% |
| Dec. 2, 2024 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Common Stock | 83640 | $51.00 | 176,029.0000 | 76,925,523 | 90.53% | 0.11% |
| Dec. 2, 2024 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 1960 | $52.17 | 92,389.0000 | 76,925,523 | 2.08% | 0.00% |
| Dec. 2, 2024 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Common Stock | 1960 | $51.00 | 94,349.0000 | 76,925,523 | 2.12% | 0.00% |
| Feb. 15, 2024 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | A | Common Stock | 18000 | $0.00 | 89,189.0000 | 74,838,292 | 25.28% | 0.02% |
| Feb. 15, 2024 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | A | Stock Option (Right to Buy) | 45000 | $0.00 | 45,000.0000 | 74,838,292 | 9999.99% | 0.06% |
| Feb. 15, 2024 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | A | Common Stock | 3200 | $0.00 | 92,389.0000 | 74,838,292 | 3.59% | 0.00% |
| Jan. 30, 2024 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 794 | $27.25 | 71,189.0000 | 74,838,292 | 1.10% | 0.00% |
| Jan. 9, 2024 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 1938 | $29.01 | 71,983.0000 | 74,838,292 | 2.62% | 0.00% |
| Jan. 8, 2024 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 1457 | $28.64 | 73,921.0000 | 74,838,292 | 1.93% | 0.00% |
| April 17, 2023 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Common Stock | 58631 | $30.86 | 134,009.0000 | 73,729,284 | 77.78% | 0.08% |
| April 17, 2023 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Stock Option (Right to Buy) | 58631 | $30.86 | 384,850.0000 | 73,729,284 | 13.22% | 0.08% |
| April 17, 2023 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Stock Option (Right to Buy) | 3292 | $30.86 | 443,481.0000 | 73,729,284 | 0.74% | 0.00% |
| April 17, 2023 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 58631 | $51.42 | 75,378.0000 | 73,729,284 | 43.75% | 0.08% |
| April 17, 2023 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 3292 | $51.42 | 75,378.0000 | 73,729,284 | 4.18% | 0.00% |
| April 17, 2023 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | M | Common Stock | 3292 | $30.86 | 78,670.0000 | 73,729,284 | 4.37% | 0.00% |
| Jan. 31, 2023 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 812 | $45.63 | 75,378.0000 | 71,728,634 | 1.07% | 0.00% |
| Jan. 10, 2023 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 590 | $42.93 | 76,685.0000 | 71,728,634 | 0.76% | 0.00% |
| Jan. 11, 2023 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 495 | $44.36 | 76,190.0000 | 71,728,634 | 0.65% | 0.00% |
| Jan. 9, 2023 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | S | Common Stock | 835 | $41.66 | 77,275.0000 | 71,728,634 | 1.07% | 0.00% |
| Jan. 5, 2023 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | A | Stock Option (Right to Buy) | 36250 | $0.00 | 36,250.0000 | 71,728,634 | 9999.99% | 0.05% |
| Jan. 5, 2023 | PTC THERAPEUTICS, INC. | $PTCT | Boulding Mark Elliott | EXEC. VP AND CLO | A | Common Stock | 17000 | $0.00 | 78,110.0000 | 71,728,634 | 27.82% | 0.02% |